This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.

Top Stories



    EC approval for Boehringer Ingelheim’s oncology treatment


    #TellingMyStory for Stroke Awareness Month

    Events and Initiatives

    ASCO 2015

    14 May 2015

    Education Hub




    Nintedanib* Lume-Lung
    1 Clinical Trial


    Afatinib* Lux-Lung 3 & 6
    Clinical Trials

    Tweets from @Boehringer